N/A N=19 Intense Pulse Light Treatment With Meibomian Gland Expression of the Upper Eyelids in Dry Eye Disease
Dry Eye
Primary: Non-invasive Tear Break up Time (TBUT) — 3.9; 4.0 seconds
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Early Phase 1 N=15 Topical Bimatoprost for Chemical Blepharoplasty
Dermatochalasis
Primary: Graded Change in Dermatochalasis — .2679 units on a scale
N/A N=16 Clinical Trial Comparing Two Non-Surgical Treatments for Severe Blepharoptosis
Blepharoptosis · Ptosis, Eyelid · Myasthenia Gravis
Primary: Interpalpebral Fissure (IPF) During Spontaneous Blink — 2.4; 4.1; 1.1 millimeters — p=<0.001
N/A N=11 Magnetic Correction of Eye Lid Paralysis
Blepharoptosis · Lagophthalmos · Facial Paralysis
Primary: Rating Scale of Skin Integrity — 0.3 units on a scale
N/A N=19 Clinical Trial to Improve the Magnetic Levator Prosthesis
Blepharoptosis · Ptosis, Eyelid · Myasthenia Gravis
Primary: Change in Interpalpebral Fissure During Eye Opening — 4.5; 6.9; 6.2; 6.3 millimeters — p=>=0.46
N/A N=3,345 Modified Instrumentation for Surgery to Correct Trichiasis
Trachoma
Primary: Number of Eyelids With Presence of Recurrent Trichiasis — 948; 1062; 721; 612 eyelids
N/A N=150 Chalazion Conservative Treatment Trial
Chalazion Unspecified Eye, Unspecified Eyelid · Chalazion Left Eye, Unspecified Eyelid · Chalazion Right Eye, Unspecified Eyelid
Primary: Number of Participants With Complete Resolution — 13; 12; 11 participants
Phase 4 N=43 The Effect of Lumify™ Eyedrops on Eyelid Position
Eyelid Droop
Primary: Palpebral Fissure Height — 9.64; 9.66; 9.92; 9.96 milimeter
N/A N=7 Minimally Invasive Holmium:YAG Laser Blepharoplasty
Lower Eyelid Entropion
Primary: Change in Lower Eyelid Bags. — 5; 5 Participants
Phase 4 N=18 Phenylephrine Versus Eyelid Taping for Muller's Muscle-Conjunctival Resection (MMCR) Evaluation
Ptosis, Eyelid
Primary: Mean MRD1 After Phenylephrine — 2.08 mm
N/A N=30 Impact of Soft Contact Lenses on Lid-Parallel Conjunctival Folds
Lid-Parallel Conjunctival Folds
Primary: Lid-Parallel Conjunctival Folds (LIPCOF) — 1.95; 1.75; 1.70; 1.40 Score
Phase 4 N=401 Topical Antibiotic Prophylaxis for Eyelids
Antibiotic Side Effect · Eyelid; Wound · Eyelid Diseases
Primary: Number of Participants With Surgical Site Infections — 0; 5 Participants — p=0.025
Phase 2 N=46 Safety and Efficacy Study of RVL-1201 in Acquired Blepharoptosis
Blepharoptosis
Primary: Humphrey Visual Field — 9.8; 12.1; 11.1; 16.1 Points seen
Phase 2 N=33 LEV102 Topical Gel in Acquired Blepharoptosis
Acquired Blepharoptosis
Primary: Percentage of Subjects With Treatment-Emergent Adverse Events [Safety and Tolerability]) — 0; 0; 0 Participants
Phase 3 N=164 Study of Safety and Efficacy of RVL-1201 in the Treatment of Blepharoptosis
Blepharoptosis
Primary: Mean Change in Number of Points Seen on the Leicester Peripheral Field Test (LPFT) in RVL-1201 Group vs. Vehicle Group — 6.3; 2.1; 7.7; 2.4 Points seen — p=<0.0001
N/A N=139 Treatment of Meibomian Gland Dysfunction and Evaporative Dry Eye
Chalazion · Dry Eye Syndromes
Primary: Meibomian Gland Assessment (Total Meibomian Gland Secretion Score) — 6.3; 5.6; 14.3; 6.1 Scores on a scale
N/A N=56 The Effect of Preoperative Ketamine on the Emergence Characteristics in Children Undergoing Entropion Surgery
Entropion
Primary: Extubation Time — 756.3; 425.9 seconds
N/A N=264 Silicone Gel for Postsurgical Scars of the Eyelid
Scarring Due to Treatment
Primary: Post-operative Scarring - Erythema — 1.67; 1.70; 1.50; 1.65 score on a scale — p=0.48
Phase 3 N=140 Study of the Safety and Efficacy of RVL-1201 in the Treatment of Acquired Blepharoptosis
Acquired Blepharoptosis
Primary: Mean Change in Number of Points Seen on the Leicester Peripheral Field Test (LPFT) in RVL-1201 Group vs. Vehicle Group — 5.2; 1.5; 6.4; 2.2 Points seen — p=<0.0001
Phase 3 N=234 Study of Safety of RVL-1201 in Treatment of Blepharoptosis
Blepharoptosis
Primary: Mean Change From Baseline in Intraocular Pressure (IOP) at Day 84 — -0.6; -0.2; -0.6; -0.2 mmHg
Phase 4 N=18 Rejuvenation of the Lower Eyelid Using a Combination of Two Hyaluronic Acid Fillers - a Pilot Study
Infraorbital Hollows
Primary: The Primary Objective of This Study is to Determine the Efficacy and Longevity of the Use of Restylane® and Perlane® in Combination for the Rejuvenation of the…
Phase 2 N=90 Phase 2 Study of XAF5 (XOPH5) Ointment for Reduction of Excess Eyelid Fat (Steatoblepharon)
Lower Eyelid Steatoblepharon (Excess Eyelid Fat)
Primary: Lower Eyelid Steatoblepharon Severity (LESS) Score--Clinician-Reported — 27; 6 participants — p=0.020
N/A N=4,914 Maximizing Trichiasis Surgery Success
Trichiasis · Surgery
Primary: Number of Eyes With Presence of Post-Operative Trichiasis Within 12 Months — 347; 504; 298 eyes — p=0.039
N/A N=197 Bilateral Lateral Rectus Recession Versus Unilateral Recess-Resect for Intermittent Exotropia
Exotropia
Primary: Number of Participants With Suboptimal Surgical Outcome as Assessed by Motor Alignment and Stereoacuity at Near by 3 Years — 43; 33 Participants — p=0.24
Phase 4 N=20 The Impact of Contact Lens Coefficient of Friction (CoF) on the Development of Lid Wiper Epitheliopathy (LWE)
Lid Wiper Epitheliopathy
Primary: Lid Wiper Epitheliopathy — 0.63; 0.25 score on a scale
Phase 2 N=48 ET-01 in Subjects With Lateral Canthal Lines
Lateral Canthal Lines · Crow's Feet
Primary: Number of Participants With a Response Defined as IGA-C (Investigators Global Assessment) Score ≤ 2 and a SSA-C (Subject Self-Assessment) Score ≤ 2 — 2; 3; 4; 2…
Phase 4 N=114 The Effect of Upneeq (Oxymetazoline Hydrochloride 0.1%) on Eyelid Position, Eye Redness, and Eye Appearance
Ptosis, Eyelid · Conjunctiva Inflamed · Eye Manifestations
Primary: Change in Palpebral Fissure Height — 1.1; -0.4 mm
Phase 1 N=17 Demodex Blepharitis Treatment Study
Chronic Blepharitis
Primary: Change in the Number of Demodex Mites — -3; -0.4 Mites
N/A N=179 Epidemiologic Analysis of Change in Eyelash Characteristics With Age in Healthy Women
Health
Primary: Eyelash Length as Measured by Digital Image Analysis (DIA) — 7.33 Millimeters (mm)
Phase 2 N=38 ET-01 in Subjects With Lateral Canthal Lines, LCL-209
Lateral Canthal Lines, LCL · Crow's Feet
Primary: Number of Participants With a Response Defined as Change in IGA-C (Investigators Global Assessment) Score by at Least 2 Ordinals From Baseline to Week 4 — 3; 1…